Evidence map›Paper›PMID 18786252›Full record

ArticleBMC medical genomics2008

Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.

Jiangang Liu, Andrew Campen, Shuguang Huang, Sheng-Bin Peng, Xiang Ye, Mathew Palakal, A Keith Dunker, Yuni Xia, Shuyu Li

Abstract read
In one paragraph

Article in BMC medical genomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiangang LiuLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. liu_jiangang@lilly.com
Andrew Campen
Shuguang Huang
Sheng-Bin Peng
Xiang Ye
Mathew Palakal
A Keith Dunker
Yuni Xia
Shuyu Li

Funding

Bioinformatics linkage of protein disorder and functionR01LM007688 · NLM · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI DUNKER, ALAN KEITH · 2003 to 2006
$1.3M
Mining the Structural Genomics Initiative for DisorderR01GM071714 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI DUNKER, ALAN KEITH · 2006 to 2009
$1.1M
Bioinformatics linkage of protein disorder and functionR56LM007688 · NLM · INDIANA UNIVERSITY INDIANAPOLIS · PI DUNKER, ALAN KEITH · 2008 to 2008
$442k
NIGMS NIH HHS R01 GM071714NLM NIH HHS R01 LM007688NLM NIH HHS R56 LM007688
6 · The paper itself

Abstract

backgroundNumerous studies have used microarrays to identify gene signatures for predicting cancer patient clinical outcome and responses to chemotherapy. However, the potential impact of gene expression profiling in cancer diagnosis, prognosis and development of personalized treatment may not be fully exploited due to the lack of consensus gene signatures and poor understanding of the underlying molecular mechanisms.

methodsWe developed a novel approach to derive gene signatures for breast cancer prognosis in the context of known biological pathways. Using unsupervised methods, cancer patients were separated into distinct groups based on gene expression patterns in one of the following pathways: apoptosis, cell cycle, angiogenesis, metastasis, p53, DNA repair, and several receptor-mediated signaling pathways including chemokines, EGF, FGF, HIF, MAP kinase, JAK and NF-kappaB. The survival probabilities were then compared between the patient groups to determine if differential gene expression in a specific pathway is correlated with differential survival.

resultsOur results revealed expression of cell cycle genes is strongly predictive of breast cancer outcomes. We further confirmed this observation by building a cell cycle gene signature model using supervised methods. Validated in multiple independent datasets, the cell cycle gene signature is a more accurate predictor for breast cancer clinical outcome than the previously identified Amsterdam 70-gene signature that has been developed into a FDA approved clinical test MammaPrint.

conclusionTaken together, the gene expression signature model we developed from well defined pathways is not only a consistently powerful prognosticator but also mechanistically linked to cancer biology. Our approach provides an alternative to the current methodology of identifying gene expression markers for cancer prognosis and drug responses using the whole genome gene expression data.

Identifiers

PMID18786252
PMCPMC2551605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.